GlassScriptPhysician profile
Leslie A Eiland
NPI 1366678922
$17,496.44
in general payments reported to CMS, 2019-2025
11 companies · $5,770 in 2025
The $5,770 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.40 · 2021: $4,825 · 2023: $297 · 2024: $6,545 · 2025: $5,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,185.00 |
| Food and Beverage | $427.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $6,525.00 | 2024-2025 | |
| Roche Diabetes Care, INC. | $2,900.00 | 2021 | |
| Roche Diagnostics Corporation | $2,870.00 | 2024 | |
| Novo Nordisk INC | $2,790.00 | 2025 | Rybelsus |
| Sanofi-Aventis U.S. LLC | $1,925.00 | 2021 | |
| Dexcom, INC. | $297.17 | 2023 | Dexcom G6 Transmitter |
| Mannkind Corporation | $59.40 | 2019 | |
| Genentech, INC. | $55.37 | 2025 | |
| Lilly USA, LLC | $30.82 | 2024 | |
| Ascensia Diabetes Care US INC. | $23.31 | 2024 | |
| Beta Bionics, INC. | $20.37 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Eiland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.